Cardiovascular drugs and therapy
Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights
Por Cheng W, Xia G, Xia H y 4 más.
Contenido en inglés
Resumen
Purpose
Emerging evidence links gut microbiota dysbiosis and its metabolites to atherosclerosis. This systematic review aims to synthesize prospective evidence on the association of gut microbiota and its metabolites with prognosis in coronary heart disease (CHD) patients.
Methods
A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted from inception to January 21, 2026. Prospective cohort studies, nested case-control studies, or prospective case-control studies reporting associations between gut microbiota features or metabolite levels and major adverse cardiovascular and cerebrovascular events (MACCE, including all-cause death, cardiovascular death, myocardial infarction, stroke, unstable angina, heart failure, and all-cause unplanned hospitalization/emergency department visits) in CHD patients were included.